ATE324450T1 - Polypeptid, das neutralisierende antikörper gegen hiv induziert - Google Patents

Polypeptid, das neutralisierende antikörper gegen hiv induziert

Info

Publication number
ATE324450T1
ATE324450T1 AT02710945T AT02710945T ATE324450T1 AT E324450 T1 ATE324450 T1 AT E324450T1 AT 02710945 T AT02710945 T AT 02710945T AT 02710945 T AT02710945 T AT 02710945T AT E324450 T1 ATE324450 T1 AT E324450T1
Authority
AT
Austria
Prior art keywords
polypeptide
antibodies against
neutralizing antibodies
against hiv
induces neutralizing
Prior art date
Application number
AT02710945T
Other languages
English (en)
Inventor
Robert Brasseur
Benoit Charloteaux
Michel Chevalier
Habib Raphaelle El
Tino Krell
Regis Sodoyer
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0100141A external-priority patent/FR2819256B1/fr
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Application granted granted Critical
Publication of ATE324450T1 publication Critical patent/ATE324450T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02710945T 2001-01-05 2002-01-04 Polypeptid, das neutralisierende antikörper gegen hiv induziert ATE324450T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0100141A FR2819256B1 (fr) 2001-01-05 2001-01-05 Polypeptide induisant des anticorps neutralisant le vih
FR0100848 2001-01-23

Publications (1)

Publication Number Publication Date
ATE324450T1 true ATE324450T1 (de) 2006-05-15

Family

ID=26212817

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02710945T ATE324450T1 (de) 2001-01-05 2002-01-04 Polypeptid, das neutralisierende antikörper gegen hiv induziert

Country Status (10)

Country Link
EP (1) EP1368478B1 (de)
AT (1) ATE324450T1 (de)
AU (1) AU2002229850A1 (de)
CA (1) CA2431881C (de)
CY (1) CY1105629T1 (de)
DE (1) DE60210936T2 (de)
DK (1) DK1368478T3 (de)
ES (1) ES2260416T3 (de)
PT (1) PT1368478E (de)
WO (1) WO2002053587A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445614A1 (de) 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verfahren zur in vitro Überwachung der Entwicklung von HIV Virus eines Individuums
EP1466924B9 (de) * 2003-04-11 2013-06-19 Institut Pasteur Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper
CN1954217B (zh) * 2004-02-06 2013-05-08 国立健康与医学研究所 衍生自gp41的多肽、含有所述多肽的疫苗组合物以及用于治疗个体HIV病毒感染的用途
WO2014020205A2 (es) * 2012-07-31 2014-02-06 Universidad De Granada Inmunógenos anti-vih mejorados
CN114605505B9 (zh) 2018-08-09 2025-04-29 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9912732A (pt) * 1998-08-03 2001-11-27 Univ Montana Estrutura molecular isolada, vìrus envelopadorecombinante, formilação de vacina, anticorpomonoclonal, anti-soro policlonal, geléia, espuma,creme ou unguento contraceptivo, amostras desangue de mamìfero e de humano, kit, linhagemcelular, processos de tratamento ou deprevenção de infecção por um vìrus em sujeito, detratamento ou de prevenção de infecção por hivem um humano, de inibição de infecção por um vìrusem uma amostra de sangue, de inibição de infecçãopor hiv em uma amostra de sangue humano, dedescontaminação de ferramentas cirúrgicas oudentais, de monitoração de produto de anticorpopara a estrutura molecular, de produção de umimunógeno para uso em uma vacina para otratamento ou a prevenção de infecção por umvìrus, e de produção de um imunólogeno para usoem uma vacina para o tratamento ou a prevençãode infecção por hiv, estrutura reticulada,anticorpo monoclonal para a estrutura, dedescontaminação de ferramentas cirúrgicas oudentais, processo de seleção de uma estruturamolecular para eficácia de vacina, mamìfero,complexo de proteìna isolado, formulação devacina, processos de imunização de um animal paraum vìrus, e de preparação de um complexo deproteìna, células fixadas, processos depurificação de um complexo de proteìna e detratamento de um hospedeiro que tem sidoexposto a um vìrus, ou de prevenção de infecçãode um hospedeiro pelo citado vìrus, e composição.
JP2003529319A (ja) * 1999-01-08 2003-10-07 キャロル ディ. ウエイス, HIV−1gp41を標的化する広範に中和する抗体を誘発する方法

Also Published As

Publication number Publication date
ES2260416T3 (es) 2006-11-01
DK1368478T3 (da) 2006-08-28
EP1368478A2 (de) 2003-12-10
AU2002229850A1 (en) 2002-07-16
DE60210936T2 (de) 2006-10-19
DE60210936D1 (de) 2006-06-01
CA2431881C (en) 2011-02-22
WO2002053587A3 (fr) 2003-09-25
PT1368478E (pt) 2006-07-31
CY1105629T1 (el) 2010-12-22
EP1368478B1 (de) 2006-04-26
CA2431881A1 (en) 2002-07-11
WO2002053587A2 (fr) 2002-07-11

Similar Documents

Publication Publication Date Title
BR0014282A (pt) Vacinas
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
PL366579A1 (en) Treatment of nail infections with no
DE60125797D1 (de) Impfstoffzusammesetzung
ATE508735T1 (de) Pulmonale verabreichung von aminoglykosiden
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
DK1328547T3 (da) Identifikation og modifikation af immundominante epitoper i polypeptider
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
DE60239682D1 (de) Vakzine, welche gp120 zusammen mit nef und/oder tat enthält, zur immunisierung gegen hiv
DK1404367T3 (da) Anvendelse af polyklonalt anti-HIV gedeserum som et terapeutisk middel
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
DE60210936D1 (de) Polypeptid, das neutralisierende antikörper gegen hiv induziert
BR0209145A (pt) Vacina contra varìola
DE69720065D1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
NO20032597D0 (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
WO2005089231A3 (en) Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
CY1108852T1 (el) Φυσικο αντισωμα ενepγο κατα του ιου hiv
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους
TW200621800A (en) Human immunodeficiency virus vaccine
AU2003255866A8 (en) Gp41 epitope and uses thereof for the treatment of hiv infections
RU2001107405A (ru) Способ повышения статокинетической устойчивости человека
FR2819256B1 (fr) Polypeptide induisant des anticorps neutralisant le vih
FR2839721B1 (fr) Antigene polypeptidique induisant des anticorps neutralisant le vih

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1368478

Country of ref document: EP